Novadaq (NVDQ) Target Trimmed at Canaccord Genuity, Buy Maintained

April 23, 2014 12:22 PM EDT Send to a Friend
Get Alerts NVDQ Hot Sheet
Price: $14.39 +0.14%

Rating Summary:
    9 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade NVDQ Now!
Join SI Premium – FREE

Canaccord Genuity analyst Jason Mills trimmed his price target on Novadaq Technologies (NASDAQ: NVDQ) from $26 to $25 but maintained a Buy rating, calling it the most compelling high growth story in small-cap med-tech.

Mills said, "We remain buyers of NVDQ, which we consider the most compelling high growth story in small-cap med-tech. We think the company possesses one of, if not the largest, TAM opportunities in the medical devices space, with a proprietary imaging platform that could eventually become ubiquitous in surgery - open and MIS.”

Mr. Mills added “We also look forward to expansion of the portfolio from fluorescent imaging to radiopharmaceuticals and other agents targeting cancer, which could emerge sooner than we expect (late 2014E).”

The analyst made no changes to his 2014 and 2015 Annual EPS estimates. Mr. Mills lowered his 2014 and 2015 Annual Revenue estimates to $50.0M and $73.5M, respectively.

For an analyst ratings summary and ratings history on Novadaq Technologies click here. For more ratings news on Novadaq Technologies click here.

Shares of Novadaq Technologies closed at $18.35 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment